Clinical Trial Update: Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating levosimendan to reduce weaning failures from extracorporeal life support in acute decompensated heart failure has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Heart Failure

Drugs mentioned

• Levosimendan (levosimendan)

Snippet

Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: Acute Decompensated Heart Failure | Phase 3 | Status: TERMINATED